| For: | Xie C, Alkhouri N, Elfeki MA. Role of incretins and glucagon receptor agonists in metabolic dysfunction-associated steatotic liver disease: Opportunities and challenges. World J Hepatol 2024; 16(5): 731-750 [PMID: 38818288 DOI: 10.4254/wjh.v16.i5.731] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v16/i5/731.htm |
| Number | Citing Articles |
| 1 |
Seyed Ebrahim Alavi, Reza Boshrouyeh, Aun Raza, Hasan Ebrahimi Shahmabadi. Multi-target incretin-based therapeutics: The rise of dual and triple agonists for metabolic disorders. European Journal of Medicinal Chemistry 2026; 305 doi: 10.1016/j.ejmech.2026.118587
|
| 2 |
Hanadi A. Hafth, Nawras A. Alwan, Eman Aboud Al-Masoudi. The effect of liraglutide on overweight and streptozotocin-induced diabetic male rats. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) 2026; 22(2) doi: 10.22141/2224-0721.22.2.2026.1691
|
| 3 |
Ibrahim S. Alhomoud, Sarah E. Wheeler, Dave L. Dixon. Repurposing incretin therapies: a narrative review of emerging indications across cardiometabolic, liver, kidney, neurological, psychiatric, and other systems. Canadian Journal of Physiology and Pharmacology 2025; 103(9) doi: 10.1139/cjpp-2025-0038
|
| 4 |
Cristian R. Perez, Mohamed A. Elfeki. Artificial Intelligence, Real Results: AI Successfully Risk-Stratifies Patients with MASLD. Digestive Diseases and Sciences 2026; doi: 10.1007/s10620-026-09831-8
|
| 5 |
Liye Zhu, Hongning Li, Yuyang Zhang, Shanshan Tao, Rengna Yan, Yong Luo, Ziyang Shen, Huiqin Li, Xiaocen Kong, Jianhua Ma. Efficacy of 12-week treatment with polyethylene glycol loxenatide in obesity or overweight patients with type 2 diabetes: a multicenter, prospective cohort study based on the flash glucose monitoring system. Frontiers in Endocrinology 2026; 17 doi: 10.3389/fendo.2026.1810786
|
| 6 |
Chrysoula Boutari, Michael A. Hill, Christos S. Mantzoros. Semaglutide, the first approved GLP-1 receptor agonist for the management of metabolic dysfunction-associated steatohepatitis. Metabolism 2026; 174 doi: 10.1016/j.metabol.2025.156397
|
| 7 |
Kathryn L. Williams, Maya Augustine, Eru Sujakhu, Justine Magadia, Lindsay Crawford, Aimee Knott, Skyler Hamilton, Uzoma Obiaka. Lipoprotein(a) in atherosclerotic cardiovascular disease, type 2 diabetes, and liver disease. Progress in Pediatric Cardiology 2025; 76 doi: 10.1016/j.ppedcard.2024.101775
|
| 8 |
Mainak Banerjee, Rimesh Pal, Sandip Pal. Histological efficacy of anti‐diabetic agents in MASH and the mediating role of weight loss: A network meta‐analysis. Diabetes, Obesity and Metabolism 2026; 28(1) doi: 10.1111/dom.70187
|
| 9 |
Maryam Zafer, Federica Tavaglione, Manuel Romero‐Gómez, Rohit Loomba. Review Article: GLP‐1 Receptor Agonists and Glucagon/GIP/GLP‐1 Receptor Dual or Triple Agonists—Mechanism of Action and Emerging Therapeutic Landscape in MASLD. Alimentary Pharmacology & Therapeutics 2025; 61(12) doi: 10.1111/apt.70196
|
| 10 |
Laura Pagès, Aina Martí-Carretero, Diego Rojo, Clara Sabiote, Farnaz Faninam, Sophia C. Parks, María Martínez-Gómez, M Serra Cusidó, Neda Akhlaghi, Sergio Muñoz-Martínez, Alba Jiménez-Masip, Juan M. Pericàs. GLP-1 and Glucagon Receptor Dual Agonists in the Management of Metabolic Dysfunction-associated Steatotic Disease (MASLD). Current Hepatology Reports 2025; 24(1) doi: 10.1007/s11901-025-00692-9
|
| 11 |
Yulin Zheng, Yi Wang, Lili Zhang, Jiandong Zhou, Yanmei Gu, Linjing Li. Association of physical activity and sedentary time with risk of non-alcoholic fatty liver disease in adults with and without diabetes mellitus. Endocrine Journal 2026; 73(2) doi: 10.1507/endocrj.EJ25-0123
|
| 12 |
Francisco Capinha, Sofia Carvalhana, Helena Cortez-Pinto. Role of Alcohol in Steatotic Liver Disease: Impact on Patients with Cardiometabolic Risk Factors. Digestive Diseases and Sciences 2025; 70(5) doi: 10.1007/s10620-025-08912-4
|
| 13 |
Yuansi Zheng, Jie Song, Qiuhui Qian, Huili Wang. Silver nanoparticles induce liver inflammation through ferroptosis in zebrafish. Chemosphere 2024; 362 doi: 10.1016/j.chemosphere.2024.142673
|
| 14 |
Queralt Martín‐Saladich, Rafael Simó, Andreea Ciudin, Julia Baguña, Clara Ramirez‐Serra, Santiago Aguadé‐Bruix, Albert Roque, Maria N. Pizzi, Hug Cuéllar, Nuria Roson‐Gradaille, Miguel A. González Ballester, Juan M. Pericàs, José Raul Herance. Phenotypic patterns of metabolic dysfunction‐associated steatotic liver disease in type 2 diabetes: The impact of insulin. European Journal of Clinical Investigation 2025; 55(9) doi: 10.1111/eci.70050
|
| 15 |
Marwin A. Farrugia, Enzo Pini, Albert Tran, Nicolas Chevalier, Rodolphe Anty, Philippe Gual. Incretins and MASLD: at the Crossroads of Endocrine and Hepatic Disorders. Current Obesity Reports 2025; 14(1) doi: 10.1007/s13679-025-00646-8
|